ConductScience.org, home

Paper496103

Risk factors for doxorubicin-induced congestive heart failure.

Von Hoff DD and 6 others. Ann Intern Med, 1979. Cited by 2,059 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Risk factors for doxorubicin-induced congestive heart failure. Papers, record 496103. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/496103

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk factors for doxorubicin-induced congestive heart failure.
PubMed
Journal
Ann Intern Med
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2,059
iCite
Relative citation ratio, by iCite
53.1
iCite
Revised in PubMed
2024-12-17
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Von Hoff DDD D
2Layard MWM W
3Basa PP
4Davis HL JrH L
5Von Hoff ALA L
6Rozencweig MM
7Muggia FMF M

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
Heart FailureMajor topic
Adolescent
Adult
Age Factors
Aged
Child
Child, Preschool
Drug Administration Schedule
Electrocardiography
Female
Heart
Humans
Infant
Male
Middle Aged
Retrospective Studies
Risk

Source PubMed

Download CSV of topics

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01708798Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast CancerBackgroundClinicalTrials.gov
NCT03000036Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer PatientsBackgroundClinicalTrials.gov
NCT03342300Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaBackgroundClinicalTrials.gov
NCT03930680Prevention of Heart Failure Induced by Doxorubicin With Early Administration of DexrazoxaneBackgroundClinicalTrials.gov
NCT04213612DCV in the Treatment of Recurrence and Refractory Childhood Solid TumorsBackgroundClinicalTrials.gov

Download CSV of trials

Cited by735

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2,059 citations.

PMIDTitleJournalYearIn PapersSource
42923061Integrated hs-cTnI, global longitudinal strain, and coronary artery calcium for risk stratification of anthracycline-related cardiac dysfunction in multiple myeloma.Front Cardiovasc Med2026https://conductscience.org/library/papers/42923061PubMed
42871672Therapy-induced senescence in breast cancer and cardiovascular disease: a double-edged biological process.Front Cardiovasc Med2026https://conductscience.org/library/papers/42871672PubMed
42670080Anthracycline Cardiotoxicity: A Real-World Study Based on FDA Adverse Event Reporting System Database.Cardiovasc Ther2026https://conductscience.org/library/papers/42670080PubMed
42615447The Quest for a Safer Use of Anthracyclines Continues: Risk Prediction of Clinical Cardiotoxicity.JACC CardioOncol2026https://conductscience.org/library/papers/42615447PubMed
42529542CARDIOVASCULAR COMPLICATIONS OF CHEMOTHERAPY IN BREAST CANCER: A SCOPING REVIEW.Ann Ib Postgrad Med2026https://conductscience.org/library/papers/42529542PubMed
42393712The mitochondrial protease, LonP1, is a potential cardioprotective target for attenuating doxorubicin-induced cardiomyocyte death.J Transl Med2026https://conductscience.org/library/papers/42393712PubMed
42389442Recovery from severe adriamycin-induced cardiomyopathy after prolonged intensive care in a patient with uterine leiomyosarcoma: A case report.Exp Ther Med2026https://conductscience.org/library/papers/42389442PubMed
42187577Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study.Curr Oncol2026https://conductscience.org/library/papers/42187577PubMed
42133079Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.Support Care Cancer2026https://conductscience.org/library/papers/42133079PubMed
42110959Integrated Cardio-oncology Service.Card Fail Rev2026https://conductscience.org/library/papers/42110959PubMed
42104397A novel green QbD-optimized RP-HPLC bioanalytical method for the simultaneous determination of doxorubicin and rifampicin in human plasma.BMC Chem2026https://conductscience.org/library/papers/42104397PubMed
42062800The Effects of Angiotensin Receptor Neprilysin Inhibitor on Endoplasmic Reticulum Stress in Doxorubicin-Mediated Cardiomyopathy-Associated Heart Failure Model in Rats.J Appl Toxicol2026https://conductscience.org/library/papers/42062800PubMed
42050190Integrating high-fidelity hiPSC-cardiomyocytes with AI-driven modeling for enhanced proarrhythmic risk assessment.Arch Toxicol2026https://conductscience.org/library/papers/42050190PubMed
42022755Doxorubicin exposure leads to cardiac fibroblast dysregulation and worsens fibrotic remodeling in the pathological heart.J Mol Cell Cardiol Plus2026https://conductscience.org/library/papers/42022755PubMed
41995966Targeting the Apelin-APJ Axis: A Promising Strategy to Mitigate Anthracycline-Induced Cardiotoxicity.Cardiovasc Toxicol2026https://conductscience.org/library/papers/41995966PubMed
41924873Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arterioscler Thromb Vasc Biol2026https://conductscience.org/library/papers/41924873PubMed
41827970AI-Enabled Precision Echocardiography: Toward Personalized Cardiovascular Care.Diagnostics (Basel)2026https://conductscience.org/library/papers/41827970PubMed
41778360Urolithin A mitigates doxorubicin-induced myocardial injury via suppression of ROS-driven apoptotic signaling.Histol Histopathol2026https://conductscience.org/library/papers/41778360PubMed
41766769Frailty Meets Cardio-oncology: A New Frontier in Personalised Cancer Care.Eur Cardiol2026https://conductscience.org/library/papers/41766769PubMed
41741472Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis.NPJ Breast Cancer2026https://conductscience.org/library/papers/41741472PubMed

See all 735 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/496103

GET https://conductscience.org/api/papers/v1/496103/cited_by?page=2